Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease

Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's diseaseLeveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving lysosomal health as a therapeutic angle for Parkinson's disease AMSTERDAM, June 11, 2026 (GLOBE NEWSWIRE) -- Scenic Biotech ("Scenic” or "the Company”), a neurometabolic company whose function‑first genomics engine has identified a first-in-class therapy to restore lysosomal function, a c